Abstract
This manuscript summarises the highlights from the virtual European Respiratory Society's “Clinical techniques, imaging and endoscopy” Assembly 14 presented at the 2021 European Respiratory Society International Congress. Cutting-edge innovative developments in both diagnostic approaches and therapeutic strategies in patients with lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases were presented on this year's interactive congress platform. In this manuscript, the Assembly 14 subgroups summarise the key take home messages given new research outcomes and place them in the context of the current knowledge.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: C Bal has nothing to disclose.
Conflict of interest: C Falster reports a fee for a lecture at a professional meeting organised by AstraZenia outside the submitted work.
Conflict of interest: A Carvalho reports lecture fees from Zambon and Boehringer Ingelheim, outside the submitted work
Conflict of interest: N. Hersch has nothing to disclose.
Conflict of Interest: J. Brock reports lecture fees and consulting activity from Boehringer Ingelheim, Streamed up! and AstraZeneca outside the submitted work.
Conflict of interest: C.B. Laursen reports a fee for a lecture at a research symposium organised by AstraZeneca outside the submitted work.
Conflict of interest: S. Walsh reports fees for lectures at research symposiums organised by Zambon and Boehringer Ingelheim outside the submitted work.
Conflict of interest: J. Annema reports research grants from Boston Scientific and Maunea Kea outside the submitted work.
Conflict of interest: D. Gompelmann reports lecture and travel fees from Pulmonx, AstraZeneca, Boehringer Ingelheim, Olympus, Chiesi, Berlin Chemie and Novartis outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received March 1, 2022.
- Accepted March 15, 2022.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
